Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: Analysis of two controlled.

Slides:

Advertisements

Similar presentations

Conclusions Sidney Cohen, MD Chairman, Department of Medicine Temple University School of Medicine Philadelphia, Pennsylvania Sidney Cohen, MD Chairman,

Advertisements

Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta- analysis Eline J.C.A. Kamp, John S. Kane, Alexander C. Ford Clinical Gastroenterology.

Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Randomized Controlled Clinical Trial of the Serotonin.

Psyllium Fiber Reduces Abdominal Pain in Children With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial Robert J. Shulman, Emily B. Hollister,

Effect of Linaclotide on Severe Abdominal Symptoms in Patients With Irritable Bowel Syndrome With Constipation Satish S.C. Rao, Eamonn M.M. Quigley,

Some Patients With Irritable Bowel Syndrome May Have Exocrine Pancreatic Insufficiency John S. Leeds, Andrew D. Hopper, Reena Sidhu, Alison Simmonette,

Efficacy of a Gluten-Free Diet in Subjects With Irritable Bowel Syndrome-Diarrhea Unaware of Their HLA-DQ2/8 Genotype Imran Aziz, Nick Trott, Rebecca.

Effect of Linaclotide on Severe Abdominal Symptoms in Patients With Irritable Bowel Syndrome With Constipation Satish S.C. Rao, Eamonn M.M. Quigley,

Volume 150, Issue 2, Pages e8 (February 2016)

Prevalence, Characteristics, and Impact of Bloating Symptoms in Patients With Irritable Bowel Syndrome Yehuda Ringel, Rachel E. Williams, Linda Kalilani,

Volume 139, Issue 6, Pages e2 (December 2010)

Volume 128, Issue 3, Pages (March 2005)

Millie D. Long, Bruce E. Sands

Charles D. Gerson, Mary-Joan Gerson

Volume 133, Issue 2, Pages (August 2007)

Diagnosis of irritable bowel syndrome

Patient-Reported Outcomes for Irritable Bowel Syndrome Are Associated With Patients' Severity Ratings of Gastrointestinal Symptoms and Psychological Factors

Factors Associated With Response to Placebo in Patients With Irritable Bowel Syndrome and Constipation Sarah Ballou, Alissa Beath, Ted J. Kaptchuk, William.

Volume 133, Issue 5, Pages (November 2007)

Treatment of Esophageal (Noncardiac) Chest Pain: An Expert Review

A Very Low-Carbohydrate Diet Improves Symptoms and Quality of Life in Diarrhea- Predominant Irritable Bowel Syndrome Gregory L. Austin, Christine B. Dalton,

Prevalence of Irritable Bowel Syndrome–type Symptoms in Patients With Celiac Disease: A Meta-analysis Anita Sainsbury, David S. Sanders, Alexander C.

A Diet Low in Fermentable Oligo-, Di-, and Monosaccharides and Polyols Improves Quality of Life and Reduces Activity Impairment in Patients With Irritable.

Volume 145, Issue 2, Pages e1 (August 2013)

Short-Bowel Syndrome Clinical Gastroenterology and Hepatology

Effect of Ramosetron on Stool Consistency in Male Patients With Irritable Bowel Syndrome With Diarrhea Shin Fukudo, Motoko Ida, Hiraku Akiho, Yoshihiro.

Volume 133, Issue 2, Pages (August 2007)

Psyllium Fiber Reduces Abdominal Pain in Children With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial Robert J. Shulman, Emily B. Hollister,

Effectiveness of proton pump inhibitors in nonerosive reflux disease

Volume 150, Issue 2, Pages e8 (February 2016)

Prevalence and Presentation of Lactose Intolerance and Effects on Dairy Product Intake in Healthy Subjects and Patients With Irritable Bowel Syndrome

Issue Highlights Clinical Gastroenterology and Hepatology

Traveling Internationally: Avoiding and Treating Travelers' Diarrhea

Volume 151, Issue 6, Pages (December 2016)

Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea Reginald V. Fant,

A Comprehensive Self-Management Irritable Bowel Syndrome Program Produces Sustainable Changes in Behavior After 1 Year Jasmine K. Zia, Pamela Barney,

Severe Constipation Clinical Gastroenterology and Hepatology

Ronnie Fass, Stephen J. Sontag, Barry Traxler, Mark Sostek

Effects of 5-Hydroxytryptamine (Serotonin) Type 3 Antagonists on Symptom Relief and Constipation in Nonconstipated Irritable Bowel Syndrome: A Systematic.

Dietary Triggers of Abdominal Symptoms in Patients With Irritable Bowel Syndrome: Randomized Placebo-Controlled Evidence Susan J. Shepherd, Francis C.

Effects of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation: A Meta-analysis Elizabeth J. Videlock, Vivian.

William D. Leslie Clinical Gastroenterology and Hepatology

Volume 151, Issue 1, Pages e6 (July 2016)

Effect of Once- or Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative Colitis Gary R. Lichtenstein,

Effect of tegaserod in chronic constipation: A randomized, double-blind, controlled trial John F. Johanson, Arnold Wald, Gervais Tougas, William D. Chey,

Efficacy of Linaclotide for Patients With Chronic Constipation

Efficacy and Safety of a Magnesium Sulfate–Rich Natural Mineral Water for Patients With Functional Constipation Christophe Dupont, Alain Campagne, Florence.

Michael Camilleri, Allen W. Mangel, Sheri E. Fehnel, Douglas A

Efficacy of a Gluten-Free Diet in Subjects With Irritable Bowel Syndrome-Diarrhea Unaware of Their HLA-DQ2/8 Genotype Imran Aziz, Nick Trott, Rebecca.

Rebecca M. Lovell, Alexander C. Ford

Some Patients With Irritable Bowel Syndrome May Have Exocrine Pancreatic Insufficiency John S. Leeds, Andrew D. Hopper, Reena Sidhu, Alison Simmonette,

Effect of renzapride on transit in constipation-predominant irritable bowel syndrome Michael Camilleri, Sanna McKinzie, Jean Fox, Amy Foxx-orenstein,

Effects of Different Coping Strategies on Physical and Mental Health of Patients With Irritable Bowel Syndrome Lilian Dindo, PhD Clinical Gastroenterology.

Rectal Mucosal Nitric Oxide in Differentiation of Inflammatory Bowel Disease and Irritable Bowel Syndrome Claudia I. Reinders, Max Herulf, Tryggve Ljung,

Risk of Irritable Bowel Syndrome After an Episode of Bacterial Gastroenteritis in General Practice: Influence of Comorbidities Ana Ruigómez, Luis Alberto.

The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: A double.

Chronic Diarrhea Clinical Gastroenterology and Hepatology

Nicolas Williet, William J. Sandborn, Laurent Peyrin–Biroulet

Severe irritable bowel and functional abdominal pain syndromes: Managing the patient and health care costs George F. Longstreth, Douglas A. Drossman

Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: Analysis of two controlled.

Issue Highlights Clinical Gastroenterology and Hepatology

Issue Highlights Clinical Gastroenterology and Hepatology

Clinical application of polymerase chain reaction to diagnose Clostridium difficile in hospitalized patients with diarrhea Michael S. Morelli, Susan.

Effect of Ramosetron on Stool Consistency in Male Patients With Irritable Bowel Syndrome With Diarrhea Shin Fukudo, Motoko Ida, Hiraku Akiho, Yoshihiro.

Rectal hyperreactivity to distention in patients with irritable bowel syndrome: role of distention rate Maura Corsetti, Bruno Cesana, Sherrie Bhoori,

Scott K. Fung, Anna S.F. Lok Clinical Gastroenterology and Hepatology

Volume 128, Issue 4, Pages (April 2005)

Volume 139, Issue 6, Pages e2 (December 2010)

Bowel Urgency in Patients With Irritable Bowel Syndrome

Self-Administered Cognitive Behavior Therapy for Moderate to Severe Irritable Bowel Syndrome: Clinical Efficacy, Tolerability, Feasibility Jeffrey M.

Presentation transcript:

Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: Analysis of two controlled trials Anthony J. Lembo, Kevin W. Olden, Vanessa Z. Ameen, Susan L. Gordon, Amy T. Heath, Eric G. Carter Clinical Gastroenterology and Hepatology Volume 2, Issue 8, Pages 675-682 (August 2004) DOI: 10.1016/S1542-3565(04)00284-8

Figure 1 IBS characteristics of populations A and B. Clinical Gastroenterology and Hepatology 2004 2, 675-682DOI: (10.1016/S1542-3565(04)00284-8)

Figure 2 Progression of patients in the study (population A). Clinical Gastroenterology and Hepatology 2004 2, 675-682DOI: (10.1016/S1542-3565(04)00284-8)

Figure 3 Percent of days alosetron- or placebo-treated patients in population A experienced satisfactory control of urgency throughout the 12-week treatment and 2-week follow-up phases (∗∗P < 0.003). Insert shows the percent of patients with satisfactory control of urgency during the first week of treatment (∗P < 0.05). •, Alosetron; ○, placebo. Clinical Gastroenterology and Hepatology 2004 2, 675-682DOI: (10.1016/S1542-3565(04)00284-8)

Figure 4 Proportion of alosetron- or placebo-treated patients in population B with more frequent urgency (i.e., lack of satisfactory control of bowel urgency for ≥10 of 14 days during screening) who improved to ≤1 day of uncontrolled urgency each week during treatment (∗P < 0.01; ∗∗P < 0.001). •, Alosetron; ○, placebo. Clinical Gastroenterology and Hepatology 2004 2, 675-682DOI: (10.1016/S1542-3565(04)00284-8)

Figure 5 Stool frequency (stools/day) and stool consistency scores at baseline, during treatment, and during follow-up period for alosetron- and placebo-treated patients in population A (∗P < 0.001). •, Alosetron; ○, placebo. Clinical Gastroenterology and Hepatology 2004 2, 675-682DOI: (10.1016/S1542-3565(04)00284-8)